Table 1.
Baseline characteristics of studies included in the network meta-analysis*
| Study | Country | Participants’ median or mean age, y | Clinical stage | Sample size | Treatments | Median follow-up, y | Outcomes |
|---|---|---|---|---|---|---|---|
| Agresti et al., 2014 (29) | Italy | 52.6 | T1N0 | 1034 | BCS+SLNB+RT (517) | 5 | OS, DFS |
| vs BCS+ALND+RT (517) | |||||||
| Arriagada et al., 2003 (30) | France | — | T1N0–1M0 | 176 | BCS+ALND+RT (88) | 22.7 | OS, DFS |
| vs M+ALND+RT (88) | |||||||
| Blichert-Toft et al., 2008 (31) | Denmark | — | Stage I–II | 793 | BCS+ALND (381) | 19.6 | OS, DFS |
| vs M+ALND (350) | |||||||
| Cabanes et al., 1992 (32) | France | 50.6 | N0–1aM0 | 658 | BCS+ALND+RT (326) | 4.5 | OS |
| vs BCS+SLNB+RT (332) | |||||||
| Canavese et al., 2016 (33) | Italy | 59 in ALND | N0 | 225 | BCS+ALND+RT (115) | 14.3 | OS, DFS |
| 56 in SLNB | vs BCS+SLNB+RT (110) | ||||||
| Chetty et al., 2000 (34) | United Kingdom | 54 | T1N0–1M0 | 446 | BCS+ANS+RT (234) | 4.1 | OS, DFS |
| vs BCS+ALND+RT (232) | |||||||
| Clark et al., 1996 (35) | Canada | — | T1N0–1M0 | 837 | BCS+ALND (421) | 7.6 | OS, DFS |
| vs BCS+ALND+RT (416) | |||||||
| Fisher et al., 2002 (36) | United States | — | T1–2N0–1M0 | 1011 | M+RT (646) | 8 | OS, DFS |
| vs M (365) | |||||||
| Fisher et al., 1995 (37) | United States | — | T1–2N0–1M0 | 3628 | M (1775) | 12 | OS, DFS |
| vs BCS+SLNB (1853) | |||||||
| vs BCS+SLNB+RT (1857) | |||||||
| Galimberti et al., 2013 (38) | United States | 53 in ALND | T1–2N0–1M0 | 931 | M+ALND (44) vs M (42) | 5 | DFS |
| 54 in non–ALND | BCS+ALND (420) vs BCS+SLNB (425) | ||||||
| Giuliano et al., 2011 (39) | United States | 56 in ALND | T1–2 | 856 | BCS+SLNB+RT (436) | 6.3 | OS, DFS |
| 54 in SLNB | vs BCS+ALND+RT (420) | ||||||
| Holli et al., 2001 (40) | Finland | 54 in RT | T1–2N0M0 | 152 | BCS+ALND+RT (80) | 6.7 | OS, DFS |
| 56 in non–RT | vs BCS+ALND (72) | ||||||
| Fyles et al., 2004 (41) | Canada | — | T1–2N0M0 | 769 | BCS+SLNB+RT (386) | 5.6 | OS, DFS |
| vs BCS+SLNB (383) | |||||||
| Hughes et al., 2013 (42) | United States | — | T1N0M0 | 636 | BCS+SLNB+RT (317) | 12.6 | OS, DFS |
| vs BCS+SLNB (319) | |||||||
| Killander et al., 2016 (43) | Sweden | 60 | T1–2N0M0 | 1178 | BCS+ALND+RT (591) | 15.6 | OS, DFS |
| vs BCS+ALND (587) | |||||||
| Kunkler et al., 2015 (44) | United Kingdom | 70 | T1–2N0M0 | 1326 | BCS+SLNB+RT (658) | 5 | OS, DFS |
| vs BCS+SLNB (668) | |||||||
| Litiére et al., 2012 (45) | United Kingdom | 50 | T1–2N0 | 868 | BCS+ALND+RT (448) | 22.1 | OS, DFS |
| vs M+ALND+RT (420) | |||||||
| Louis–Sylvestre et al., 2004 (46) | France | 52 in ALND | T1–2N0M0 | 658 | BCS+ALND+RT (326) | 15 | OS, DFS |
| 50.6 in ART | vs BCS+SLNB+ART+RT (332) | ||||||
| Martelli et al., 2014 (47) | Italy | 70.8 | T1N0 | 219 | BCS+ALND+RT (109) | 12.5 | OS, DFS |
| vs BCS+SLNB+RT (110) | |||||||
| Newman et al., 1999 (48) | United States | 52 | T1–2N0M0 | 211 | BCS+SLNB+RT (42) | 5.6 | OS, DFS |
| vs M (168) | |||||||
| Poggi et al., 2003 (49) | United States | 50 | T1–2N0–1M0 | 237 | M+ALND (116) | 18.4 | OS, DFS |
| vs BCS+ALND+RT (121) | |||||||
| Polgár et al., 2013 (50) | Hungary | 59 in IORT | T1N0–1M0 | 258 | BCS+SLNB+IORT (128) | 10.2 | OS, DFS |
| 58 in RT | vs BCS+SLNB+RT (130) | ||||||
| Pötter et al., 2007 (51) | Austria | 66 | T1–2N0 | 869 | BCS+ALND+RT (414) | 4.5 | OS, DFS |
| vs BCS+ALND (417) | |||||||
| Sarrazin et al., 1989 (52) | France | — | T1N0–1M0 | 179 | M (91) | 10 | OS |
| vs BCS+SLNB+RT (88) | |||||||
| Sato et al., 2017 (53) | Japan | 44.0 in IORT | T1–2N0–1M0 | 184 | BCS+SLNB+IORT (99) | 3.8 | DFS |
| 42.4 in RT | vs BCS+SLNB+RT (85) | ||||||
| Sjöström et al., 2017 (54) | Sweden | 60 | T1–2N0M0 | 932 | BCS+ALND+RT (474) | 15.2 | OS |
| vs BCS+ALND (458) | |||||||
| Strnad et al., 2016 (55) | Germany | 62 | T1–2N0–1M0 | 1184 | BCS+SLNB+IORT (633) | 9 | OS, DFS |
| vs BCS+SLNB+RT (551) | |||||||
| Tinterri et al., 2014 (56) | Italy | — | T1–2N0–1M0 | 749 | BCS+SLNB+RT (376) | 9 | OS, DFS |
| vs BCS+SLNB (373) | |||||||
| van Dongen et al., 2000 (57) | Netherlands | — | T1–2N0M0 | 868 | BCS+SLNB+RT (448) | 13.4 | OS, DFS |
| vs M (420) | |||||||
| Veronesi et al., 2001 (58) | Italy | — | T1–2N0M0 | 579 | BCS+ALND+RT (294) | 9 | OS, DFS |
| vs BCS+ALND (273) | |||||||
| Veronesi et al., 2003 (59) | Italy | — | T1N0M0 | 516 | BCS+ALND+RT (257) | — | OS, DFS |
| vs BCS+SLNB+RT (259) | |||||||
| Veronesi et al., 2005 (60) | Italy | 57 | T1N0M0 | 435 | BCS+SLNB+ART+RT (221) | 5.2 | OS, DFS |
| vs BCS+SLNB+RT (214) | |||||||
| Veronesi et al., 2013 (61) | Italy | — | T1N0–1M0 | 1305 | BCS+SLNB+IORT (651) | 5.8 | OS, DFS |
| vs BCS+SLNB+RT (654) | |||||||
| Voogd et al., 1996 (62) | Netherlands | 51.6 in BCS | T1N0–1M0 | 921 | BCS+ALND (464) | 6.2 | OS, DFS |
| 58.3 in mastectomy | vs M+ALND (457) | ||||||
| Wickberg et al., 2014 (63) | Sweden | 59.0 in RT | T1N0M0 | 381 | BCS+ALND+RT (184) | 13 | OS |
| 60.9 in non–RT | vs BCS+ALND (197) | ||||||
| Winzer et al., 2004 (64) | Germany | — | T1N0M0 | 361 | BCS+ALND (159) | 5.9 | OS, DFS |
| vs BCS+ALND+RT (188) |
The number in parentheses under the column of Treatments is the number of patients included per group. BCS+ALND = breast–conserving surgery+axillary lymph node dissection; BCS+ALND+RT = breast–conserving surgery+axillary lymph node dissection+radiotherapy; BCS+ANS+RT = breast–conserving surgery+axillary node sample+radiotherapy; BCS+SLNB = breast–conserving surgery+sentinel lymph node biopsy; BCS+SLNB+ART+RT = breast–conserving surgery+sentinel lymph node biopsy+axillary radiotherapy+radiotherapy; BCS+SLNB+IORT = breast–conserving surgery+sentinel lymph node biopsy+intraoperative radiotherapy. BCS+SLNB+RT = breast–conserving surgery+sentinel lymph node biopsy+radiotherapy; DFS = disease-free survival; M = mastectomy; M+ALND = mastectomy+axillary lymph node dissection; M+ALND+RT = mastectomy+axillary lymph node dissection+radiotherapy; M+RT = mastectomy+radiotherapy; OS = overall survival.